Compare Amgen, Inc. (AMGN) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs BigBearai Holdings Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while BigBearai Holdings Inc trades at $3.33 (market cap $1.55B). The key difference: Amgen, Inc. is far larger — about 145.6× BigBearai Holdings Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | BBAI | |
|---|---|---|
Market Cap | $225.71B | $1.55B |
Sector | Health | Technology |
52-Week High | $417.20 | $8.91 |
52-Week Low | $271.18 | $2.61 |
Enterprise Value | $269.02B | $1.25B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
BBAI trades at $3.27, up 8.64% with a bullish technical signal despite negative profitability metrics. The company reported Q2 2026 revenue growth of 13% and beat EPS estimates, though it remains unprofitable with a -65.2% net income margin. Recent news highlights defense contract execution and generative AI platform expansion for government clients.
The outlook remains challenging due to persistent losses and negative cash flow from operations, though analyst consensus leans neutral with 75% hold ratings. Key risks include execution on government contracts and achieving profitability, while technical indicators suggest near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
